MRTX News and Press, Mirati Therapeutics Inc. From 11/17/21

Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers PR Newswire SAN DIEGO , Nov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a c...

Mirati Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire SAN DIEGO , Nov. 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, today announced the pricing of an underwritte...

Mirati Therapeutics (NASDAQ:MRTX) plans to offer and sell in an underwritten public offering $500M of shares; underwriters granted 30-day option to purchase up to an additional 15% of the total shares. Offer size, terms have not yet been disclosed. For further details see: Mirati T...

The following slide deck was published by Mirati Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Mirati Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation

Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference PR Newswire SAN DIEGO , Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at...

Mirati Therapeutics, Inc. (MRTX) Q3 2021 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants David Meek – CEO Ryan Asay – Vice President of Corporate Affairs at Mirati Charles Baum – President, Founder and Head of Research and Development Dr. Jame...

Mirati Therapeutics (NASDAQ:MRTX): Q3 GAAP EPS of -$1.55 beats by $1.47. Revenue of $71.8M (+529.8% Y/Y) beats by $70.39M. Press Release For further details see: Mirati Therapeutics EPS beats by $1.47, beats on revenue

Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates Began submission of the New Drug Application for adagrasib for the treatment of patients with previously treated KRAS G12C-mutated non-small cell lung cancer under the Real-Time Oncolog...

Mirati is competing with Amgen in the KRAS G12C mutant NSCLC space. Data is compelling, but a lot of the good news potential is priced into the nearly $9bn valuation. I believe market enthusiasm will push MRTX up, and I hate to buy on market enthusiasm. For further details s...

Regional banks provided a significant bright spot on a generally lackluster session on Monday. A more than 20% gain in Silvergate Capital (NYSE:SI) led the sector higher, as investors focused on the company's cryptocurrency operations, part of a diversification that has marked the space recen...